Approved in 2010, Saxenda (liraglutide) was the first GLP-1 medication approved for weight loss in adults with obesity or overweight with at least one weight-related health issue
Additionally, we performed meta-analyses and produced comparative estimates for safety and tolerability outcomes, which are equally important to efficacy measures when deciding on optimal diabetes therapy in clinical practice
TNF- and MCP-1 expression was once again attenuated in human peripheral blood mononuclear cells
J.JonassenT.RittigS.et al
This coordinated engagement across the pancreas, brain, gut, liver, and adipose tissue underlies the mechanistic rationale for dual GLP-1/GIP receptor agonists, and explains why they have been described as super GLP-1RAs, reflecting genuine potentiation of GLP-1 action by GIP receptor agonist co-activation
difficulty breathing or swallowing) Changes in vision Signs of kidney problems (changes in urination) Signs of gallbladder problems Additional Contraindications According to prescribing information, semaglutide should be used with caution or avoided in patients with history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy
